Low Serum Adropin Levels are Associated with Coronary Slow Flow Phenomenon.

Background: Adropin is a peptide hormone expressed in coronary artery endothelial cells, which plays a potential endothelial protective role. We sought to assess whether serum adropin levels are correlated with the coronary slow flow phenomenon (CSFP).

Methods: We enrolled 82 patients with angiographically confirmed CSFP and 184 age-matched controls.

Serum salusin-β levels are associated with the presence and severity of coronary artery disease.

Objectives: We sought to assess whether serum salusin-β levels are correlated with the presence and severity of coronary artery disease (CAD).

Methods: We measured serum salusin-β levels in 278 consecutive patients undergoing coronary angiography (CAG) for the evaluation of CAD and in 126 healthy controls. Serum salusin-β levels were measured by enzyme-linked immunosorbent assay.

Serum S100A12 concentrations are correlated with angiographic coronary lesion complexity in patients with coronary artery disease.

The neutrophil activation marker S100A12 is an important pro-inflammatory cytokine and a potential biomarker for a range of inflammatory diseases. This study aims to investigate whether serum S100A12 concentrations are associated with angiographic coronary lesion complexity in patients with coronary artery disease (CAD). We enrolled 240 CAD and 68 healthy controls.

Postprocedural serum sLOX-1 levels are associated with coronary in-stent restenosis in patients with stable coronary artery disease.

Objectives: We tested whether serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) levels are able to predict in-stent restenosis (ISR) after successful primary percutaneous coronary intervention (PCI).

Methods: Preprocedural and postprocedural serum sLOX-1 levels were measured in 210 consecutive patients with stable coronary artery disease who underwent successful primary PCI for de novo lesions. The patients were grouped as ISR and non-ISR based on angiographic follow-up results.

Serum sLOX-1 levels are associated with the presence and severity of angiographic coronary artery disease in patients with metabolic syndrome.

Purpose: Patients with metabolic syndrome are at high-risk for development of atherosclerosis and cardiovascular events. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1(sLOX-1) is associated with coronary artery disease (CAD) and metabolic disorders. We sought to assess whether serum sLOX-1 levels are correlated with the presence and severity of CAD in patients with metabolic syndrome (MetS) undergoing coronary angiography.